What You Should Know:
- Noom has launched Proactive Health Microdose GLP-1Rx, a first-of-its-kind preventive health program designed to intervene before chronic disease takes root.
- Available to individuals with a BMI of 21 or higher, the offering combines personalized microdoses of GLP-1 medication with comprehensive at-home biomarker testing and Noom’s digital behavior modification platform.
- Priced at $149 per month, the program aims to shift the healthcare paradigm
Read More
GLP-1
PHTI Report 2025: 5 Strategies for Employers to Manage GLP-1 Costs and Coverage
What You Should Know:
- The Peterson Health Technology Institute (PHTI) has released a critical purchasing guide for employers struggling to manage the skyrocketing costs of GLP-1 obesity medications.
- The report recommends a shift away from broad, unchecked coverage toward a managed approach focused on three phases: Initiation (strict eligibility), Maintenance (adherence support), and Supported Discontinuation (managing off-ramps).
- PHTI urges employers to demand
Read More
Castlight and Noom Join Forces to Tackle the GLP-1 Cost Crisis Through Integrated Digital Health
What You Should Know:
- Castlight Health and Noom have formed a strategic partnership to embed Noom’s preventive health and weight management programs directly into Castlight’s health navigation platform.
- The integration allows employers to purchase Noom through Castlight, granting employees seamless access to psychology-based care and GLP-1 medication management. The move is designed to combat rising healthcare costs by pairing expensive pharmaceutical interventions with
Read More
Dietitian Live’s Quantum Mind Architecture™: How Subconscious Rewiring is Reversing Type 2 Diabetes Without GLP-1s
What You Should Know:
- Dietitian Live, a pioneering healthcare startup, today announced a breakthrough demonstrating that subconscious belief patterns are the primary driver of healing in chronic metabolic disease.
- Its patent-pending Quantum Mind Architecture™ program achieved an 81% reversal to normal A1C levels in pre-diabetes and 28% reversal in Type 2 Diabetes without GLP-1s in a same-cohort study. The company is advocating for the creation of a new field: subconscious
Read More
GoodRx Launches $199 Ozempic and Wegovy Pricing, Unveils Telemedicine for GLP-1 Access
What You Should Know:
- GoodRx has unveiled two major initiatives to democratize access to GLP-1 medications: the launch of the GoodRx for Weight Loss telemedicine subscription and a new introductory cash price of $199 per month for Ozempic® and Wegovy® injection pens through a partnership with Novo Nordisk.
GoodRx for Weight Loss Telemedicine
GoodRx for Weight Loss, a direct-to-consumer telemedicine subscription is designed to simplify and manage every step of the GLP-1 treatment
Read More
Trump Unveils Historic Drug Price Cuts: Ozempic and Wegovy Reduced to $350 via TrumpRx
What You Should Know:
- President Donald J. Trump announced the latest in a series of significant actions to lower prescription drug prices, unveiling agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk.
- The initiative delivers historic price reductions on some of the world’s most popular drugs, impacting millions of Americans struggling with chronic diseases, diabetes, heart disease, and obesity.
Price Reductions for Patients and
Read More
Evolv Launches GLP-1 Supplement, a Natural Alternative to Weight-Loss Drugs
What You Should Know:
- Pioneering biomimetics company Evolv introduces its first product Evolv GLP-1: the first ingestible, natural GLP-1 peptide designed for effective and accessible weight management
- The oral GLP-1 supplement was created using a proprietary yeast strain engineered to produce a new molecule that delivers the full power of GLP-1 naturally. Unlike synthetic drugs, this non-habituating supplement is designed to help individuals manage appetite and metabolism without
Read More
Ciba Health Launches Nation’s First GLP-1 Step-Down Program, Addressing Post-Medication Metabolic Health
What You Should Know:
- Ciba Health today announced the launch of its new GLP-1 Step-Down Program, marking the first national offering designed to guide individuals off popular weight loss medications like Ozempic and Wegovy.
- Ciba Health's virtual program aims to help members either avoid GLP-1 medications entirely or safely taper off them by rebuilding metabolic health through personalized care.
Addressing an Overlooked Gap in GLP-1 Care
GLP-1s, originally developed
Read More
GLP-1 Patients Missed Over $10M in Potential Savings in a Single Quarter, Report Finds
What You Should Know:
- A new data analysis from DoseSpot, a leader in e-prescribing and healthcare technology solutions, found that 92 percent of GLP-1 prescriptions the company processed in Q1 2025 could have been filled at a lower price. This translates to a staggering $10.2M in missed savings for patients on these popular medications.
- The analysis of over 100,000 prescriptions highlights a significant gap in cost transparency and access to savings programs, contributing to the
Read More
American College of Cardiology Recommends GLP-1s as First Line Treatment Option
What You Should Know:
- The American College of Cardiology (ACC) has published a new Concise Clinical Guidance (CCG) report, providing a comprehensive framework for clinicians to medically manage obesity using the "ever-expanding set of tools to assist patients in diagnosis, weight reduction, and CVD risk mitigation."
- The new guidance, published in the Journal of the American College of Cardiology (JACC), addresses the multiple causes of obesity and outlines a clinical
Read More
